Table 4.

Studies on APOE and AD in the Latin American population.

Population	Cases/controls (n)	AD diagnosis	OR (95% CI)	ε4 frequencies (%) (cases/controls)
“Hispanics” [22]	261/267	Probable or definite	ε3ε4: 2.2 (1.3–3.4) ε4ε4: 2.2 (0.7–6.7) = n.s.	19.2/11.0 = 1.7
“Hispanics” Caribbean [23]	145/516	Unspecified	ε4 carriers: 1.1 (0.7–1.6) = n.s.	14.8/14.1 = 1.0
“Hispanics” [24]	140/219	Unspecified	APOE ε4 heterozygous: 1.6 (1.1–2.3) APOE ε4 homozygous: 2.5 (1.1–5.7)	19.0/10.0 = 1.9
Mexico [25]	28/28	Probable and possible	ε4 carriers: 2.04 (0.59, 7.10) = n.s.	21.4/12.5 = 1.7
Mexico [26]	49/141	Unspecified	ε4 carriers: 1.01 (0.45–2.23) = n.s.	13.2/10.9 = 1.2
Cuba [27]	80/21	Probable	ε4 carriers: 4.33 (1.27–14.79)	25.0/7.1 = 3.6
Cuba [28]	273/2247	Any dementia diagnosis	ε3ε4: 2.59 (2.04–3.28) ε4ε4: 2.88 (1.58–5.27) ε4 carriers: 2.47 (1.96–3.12)	17.4/8.0 = 2.2
Brazil [29]	104/108	Unspecified	ε4 carriers: 3.63 (2.19–6.03)	33.1/12.0 = 2.8
Brazil [30]	120/120	Probable	ε3ε4: 3.22 (1.73–6.01) ε4ε4: 9.57 (2.07–44.13) ε4 carriers: 4.35 (2.45–7.78)	31.0/10.0 = 3.1
Argentina [31]	45/45	Probable	ε4 carriers: 3.33 (1.20–9.02).	22.0/7.7 = 2.9
Venezuela [32]	121/1665	Unspecified	ε4 carriers: 2.97 (1.87–4.71)	17.0/11.0 = 1.5
Venezuela [33]	79/100	Unspecified	ε3ε4: 1.93 (1.02–3.70) ε4ε4: 4.29 (1.32–13.90)	34.8/16.0 = 2.2
Chile [34]	95/187	Probable and possible	ε3ε4: 2.4 (1.3–4.5) ε4ε4: 12.8 (3.9–47.6) ε4 carriers: 2.9 (1.7–5.1)	40.0/19.0 = 2.1
Colombia [35]	181/181	Unspecified	APOE ε4 heterozygous: 5.51 (3.32–9.16) APOE ε4 homozygous: 21 (2.79–6.48)	58.0/13.0 = 4.5
Colombia [36]	83/44	Probable and possible	ε4 carriers: 5.1 (1.9–13.6)	23.4/6.8 = 3.4
Colombia [36]	39/44	Probable	ε4 carriers: 7.4 (2.5–22.0)	30.8/6.8 = 4.5
Ecuador [21]	39/39	Unspecified	ε3ε4: 2.15 (0.6–7.9) = n.s. ε4ε4: 2.58 (0.2–76.8) = n.s.	17.9/10.3 = 1.7
Ecuador (current study)	56/58	Probable	ε4 carriers: 7.286 (2.824–18.799)	33.9/6.0 = 5.7

n.s.: no significant effect.